Table 1.

Clinical characteristics of the patients

PatientGenderAge at Onset of NS (yr)Age at the Time of the Study (yr)No. of Relapses after Last CPCumulative CP Dosage (mg/kg)Height (cm)BMI (kg/m2)BP (mmHg)Current MedicationsDuration of CsA Therapy (mo)Duration of Remission (mo)
1M3.04220248156.524.5126/80Pred, CsA, ena, Ca720.6
2M1.23229412173.520.2112/70Pred1150.9
3M6.4177154183.519.8125/80CsA1090.4
4M2.72812176174.022.0130/70Pred, FK560, ena7214.9
5M2.53641414159.517.6120/75Tri, peri661.6
6M2.2329182183.531.0120/80Pred, CP585.7
7M3.03210129184.031.4115/70-7130.0
8M3.62034165175.022.2140/70Pred, CsA, MMF1350.1
9M7.72314158200.022.2155/88-017.2
10M4.81618168159.517.7115/70MMF281.6
11M3.042Unknown334177.023.5118/80Atenolol12441.2
12M5.01926168169.018.8136/64CsA, Ca1445.0
13F2.61816150172.019.2110/70Pred, tacro, MMF, ena, vitD, Ca810.3
14F7.32330Unknown162.520.5120/80Pred, los1485.7
15F2.626>50387175.025.9138/86Pred, CsA17433.6
  • Ca, calcium; ena, enalapril; los, losartan; MMF, mycophenolate mofetil; peri, perindopril; pred, prednisone; tacro, tacrolimus; tri, triamcinolone; vitD, vitamin D.